



HHS Public Access

Author manuscript

Chronic Stress (Thousand Oaks). Author manuscript; available in PMC 2017 June 23.

Published in final edited form as:

Chronic Stress (Thousand Oaks). 2017 February ; 1: .

Oxytocin and Stress-related Disorders: Neurobiological Mechanisms and Treatment Opportunities

Lauren M. Sippel^{1,2}, Casey E. Allington³, Robert H. Pietrzak^{1,2}, Ilan Harpaz-Rotem^{1,2}, Linda C. Mayes⁴, and Miranda Olff^{5,6}

¹U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, Clinical Neurosciences Division, VA Connecticut Healthcare System, West Haven, CT, USA ²Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA ³Veterans Affairs Connecticut Health Care System, West Haven, CT, USA ⁴Yale Child Study Center, New Haven, CT, USA ⁵Department of Psychiatry, Academic Medical Center, University of Amsterdam, The Netherlands ⁶Arq Psychotrauma Expert Group, Diemen, The Netherlands

Abstract

Novel pharmacotherapies that improve outcomes for individuals with stress-related psychiatric disorders are needed. The neurohormone oxytocin (OT) is a promising candidate given its influence on the social-emotional brain. In this review, we present an overview of evidence supporting OT's utility for treating major depressive disorder and posttraumatic stress disorder. We first discuss endogenous OT, which research suggests is not yet a reliable biomarker of stress-related disorders. Second, we review effects of intranasal (IN) OT on processes relevant to stress-related disorders in healthy populations (anhedonia, reward processing, psychosocial stress reactivity, fear/anxiety, and social behavior) and their neurobiological mechanisms (e.g., the salience network and hypothalamic-pituitary-adrenal axis). Third, we present the sparse but promising findings from clinical populations, followed by discussion of critical moderating variables to consider in the service of maximizing the therapeutic potential of OT (e.g., patient sex and child maltreatment). We also identify heterogeneous findings and limitations of existing research, including reliance on single-dose studies in psychiatrically healthy samples and unanswered questions regarding the effectiveness of IN drug delivery and dosing schedules. Well-controlled multidose studies including women and measures of potentially moderating variables are sorely needed and would inform our understanding of the utility of OT for preventing and treating stress-related psychiatric disorders.

Creative Commons Non Commercial CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (<http://www.creativecommons.org/licenses/by-nc/3.0/>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>). Reprints and permissions: sagepub.com/journalsPermissions.nav

Corresponding author: Lauren M. Sippel, National Center for Posttraumatic Stress Disorder, Clinical, Neurosciences Division, VA Connecticut Healthcare System, 950 Campbell Ave 151D, West Haven, CT 06517, USA. lauren.sippel@va.gov.

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Pietrzak has received travel funds from Johnson & Johnson for work that is unrelated to this project.

Keywords

Intranasal oxytocin; pharmacology; posttraumatic stress disorder; major depressive disorder; anxiety; psychotherapy; fear; reward; sex; context

Introduction

The stress response is composed of cognitive, behavioral, and physiological processes that restore homeostasis and ensure survival. Cognitive appraisal of perceived threats and environmental stressors is mediated by the brain to determine cardiovascular, immune, and neuroendocrine processes, all of which can be adaptive or maladaptive.^{1,2} Brain areas involved in the stress response include the hippocampus and hypothalamus, both targets of gluco-corticoids (e.g., cortisol); the brain stem, which mediates autonomic stress responses; the prefrontal cortex (PFC), which downregulates neurobiological stress responses; the amygdala, which regulates threat appraisal and coordinates automatic neurophysiological and behavioral responses to threat; and the striatum, which mediates threat appraisal value. Acute stress resulting from a specific event or situation and chronic stress resulting from repeated exposure to stressful situations increases risk for the development of psychopathology, as well as social dysfunction that can maintain psychopathology.³ Posttraumatic stress disorder (PTSD) can develop following exposure to trauma, a specific type of acute stressor that includes actual or threatened death, serious injury, or sexual violation and results in trauma-related intrusions, avoidance of trauma cues, changes in cognitions and mood, and hyperarousal.⁴ Major depressive disorder (MDD), which is characterized predominantly by sad mood and loss of interest, has been proposed to develop from perceived uncontrollable stress.⁵ PTSD and MDD share a number of mechanisms,⁶ including anhedonia,^{7,8} psychosocial stress reactivity,^{9,10} anxiety,¹¹ and alterations in social behaviors, such as low social support,¹² social withdrawal,¹³ reduced trust,¹⁴ and poorer bonding and attachment,^{15,16} which may serve as risk and maintenance factors for stress-related psychopathology.

The neurohormone oxytocin (OT) is associated with or influences processes implicated in MDD and PTSD, making the oxytocinergic system potentially relevant to the development, maintenance, and treatment of these disorders. In this review, we examine the role of OT in stress-related disorders, with emphasis on experimental studies of the effects of intranasal (IN) OT on relevant neurobiological and behavioral processes. We first review existing evidence for the role of endogenous peripheral OT in stress-related disorders. Second, we review effects of IN OT on processes relevant to stress-related disorders in healthy populations and their potential neurobiological mechanisms. Third, we review findings in clinical populations and discuss critical moderating variables that should be considered in the service of maximizing therapeutic potential of OT for stress-related disorders. Throughout the review, we highlight oxytocin's capacity to amplify responses to salient stimuli, irrespective of valence, as well as heterogeneity in findings. Given the brevity of this review, evidence that OT receptor distribution in the brain varies in a species-specific manner,¹⁷ and extensive basic science and translational research in animal models,^{3,18} we will focus on human subjects research.

Oxytocin

OT, a nine amino acid peptide hormone produced by the hypothalamus, plays a vital role in many physiological functions, including labor induction and lactation.¹⁹ OT, in dynamic interplay with arginine vasopressin (AVP), also regulates human emotions, social cognition, and social behaviors,²⁰ thus spanning two Research Domain Criteria (RDoC) domains proposed by the U.S. National Institute of Mental Health: negative valence systems and social processes.^{21,22} OT is released to several brain areas relevant to stress-related disorders, including the amygdala, hypothalamus, hippocampus, nucleus accumbens, insula, and striatum,²³ and effects of OT are mediated by OT receptors found in these regions.¹⁷

Endogenous OT

Given lack of access to central measures of OT, investigators have measured endogenous peripheral OT in urine, saliva, or plasma to examine which factors precipitate OT release. While debate remains about whether peripheral measures of OT relate to central measures,^{24,25} animal research has revealed coupled central and peripheral OT release during stress²⁶ and axonal projections from magnocellular OT neurons to forebrain structures, the amygdala, and the posterior pituitary.²⁷ Stimulation of these projections has also been found to lead to an increased release of OT to the periphery and the brain, with accompanying reductions in fear-related behavior mediated by the amygdala.²⁷ In humans, peripheral OT has been shown to increase during acute stress,^{28,29} in response to affiliative touch,³⁰ and following interpersonal stress,³¹ perhaps promoting affiliative behaviors that facilitate relationship repair.³² However, as will be evident throughout this review, findings are not entirely consistent; for example, several studies did not detect significant stress-,³³ touch-,³⁴ and interpersonal interaction-related³⁵ changes in peripheral OT concentrations.

Existing evidence suggests that peripheral OT is currently not a reliable biomarker for psychiatric disorders. Studies of plasma OT in depressed individuals, for example, have revealed both elevated and reduced levels, and studies of plasma OT in PTSD have shown a lack of main effects,³⁶ but revealed important moderating variables.^{37,38} A recent systematic review of eight studies revealed an inverse relationship between peripheral OT and depressive symptom severity in pregnant women, but associations between depressive symptom severity and high, low, and variable OT levels in non-pregnant women.³⁹ In men, peripheral OT and depressive symptoms were positively but not significantly associated. A meta-analysis of 64 studies of several psychiatric disorders, including MDD but not PTSD, showed no significant differences in peripheral OT between healthy and psychiatric groups (except in anorexia).⁴⁰ Compared with trauma-exposed controls, lower peripheral OT levels have been observed in men, but not women, with PTSD,³⁷ and among PTSD patients without childhood trauma (whereas PTSD patients with a history of childhood trauma were found to have higher plasma OT levels relative to controls).³⁸

Existing studies of peripheral OT and psychopathology have been limited by small samples; a high degree of methodological heterogeneity, including measurement of basal versus post-challenge levels; correlating plasma OT with symptom severity versus diagnosis; variability in patients' other treatments that may have affected OT levels; inclusion of only women instead of both sexes; and questionable reliability of assay methods.^{41,42} For example, there

are large discrepancies in OT levels measured from unextracted and extracted plasma.⁴³ Values derived from unextracted samples have been found to be two orders of magnitude higher, likely because molecules besides OT are tagged and detected.⁴²

Exogenous OT

Intravenous or intranasal administration of exogenous OT allows for experimental examination of the causal effects of OT on human behavior. To date, most experimental research on OT has utilized intranasal administration (IN OT) given its convenience, noninvasiveness, and safety.⁴⁴ IN OT pharmacokinetics are not fully understood, and definitive evidence for how much OT, a large peptide, reaches target brain areas via IN delivery is lacking;²³ however, there is accumulating evidence for nose-to-brain pathways exerting neural and behavioral effects in both animals^{45,46} and humans.⁴⁷ The first delivery sites of IN OT are the olfactory bulbs and brainstem, which output to the amygdala via local GABAergic circuits.⁴⁸ IN OT may thus enter the central nervous system, mimicking “neurohormonal” OT release; alternatively, IN OT may act peripherally to affect behavior via OT receptors.²⁵ The presence of OT receptors in many sites in the periphery suggest that it has broad effects,²⁵ but possible long-term neuronal and molecular side effects have not been systematically measured. Further, other methods of administration (e.g., aerosol⁴⁹) may prove to be more optimal given the many factors that can influence the effectiveness of transmucosal nasal drug delivery⁵⁰ and the very modest amount that reaches cerebrospinal fluid (CSF; 0.0005% within 1 h of administration),²⁵ though IN OT may penetrate brain regions without entering CSF.

IN OT Increases Reward Processing

Stress reduces hedonic capacity and reward responsiveness.⁵¹ As such, PTSD and MDD are both characterized by anhedonia and dysregulation of the brain’s reward system.^{9,52} Accordingly, the inability to inhibit the influence of negatively valenced stimuli on cognitive and emotional responses is thought to contribute to the onset and maintenance of MDD.⁵³ IN OT has been shown to increase motivational salience due to association with reward⁵⁴ and neural responses to generic and personalized friendly faces in reward pathways (e.g., ventral tegmental area, striatum, and insula).^{55–57} IN OT has also facilitated detection of implicitly presented happy faces⁵⁸ and improved recognition of positive emotions,⁵⁹ which may serve as mechanisms of increased approach behavior toward positive social stimuli after IN OT.^{60,61} However, some studies have reported null effects with respect to facial affect recognition,⁶² improved recognition of fear, but not other emotions (including happiness),⁶³ and increased responding of the reward pathway in response to loss or punishment.⁶⁴

IN OT Reduces Psychosocial Stress Reactivity

Psychosocial stress and accompanying neurobiological changes elicited by tasks like the Trier Social Stress Test (TSST; a psychosocial stressor paradigm including a mock job interview and mental arithmetic test in front of judges) appear to be modulated by IN OT. In cocaine-dependent individuals, the positive association between early life stress and cortisol reactivity to the TSST was reduced among participants administered IN OT.⁶⁵ Using related tasks, IN OT was shown to reduce anticipatory anxiety⁶⁶ and cortisol release.⁶⁷ Other studies have shown opposite effects: for example, IN OT was found to increase post-TSST

cortisol in men, potentially due to OT binding with receptors for a structurally similar hormone AVP, which is associated with cortisol release.⁶⁸

IN OT Reduces Fear and Anxiety

IN OT has been shown to have anxiolytic effects, likely mediated by effects on the limbic system, including modulation of serotonin (5-HT) activity within the amygdala,⁶⁹ within which OT receptors are dense.⁷⁰ IN OT has been shown to promote fear extinction recall,^{71,72} a critical mechanism of exposure-based therapies. IN OT has also been found to reduce amygdala activation in modulation of autonomic fear⁷³ and in response to stimuli that were aversively conditioned.⁷⁴ Meta-analytic findings suggest that IN OT increases activity in prefrontal cortical areas that mediate emotion regulation and fear inhibition.⁷⁵ IN OT has also been found to increase connectivity between the amygdala and prefrontal areas responsible for fear inhibition⁷⁶ and decrease activity between the amygdala and brainstem regions implicated in autonomic and behavioral manifestations of fear.⁷⁷ However, IN OT has also been shown to enhance fear conditioning when administered before the conditioning phase,⁷⁸ to potentiate acoustic startle responses to negative social stimuli,⁷⁹ and to impede response to a single-session exposure treatment for arachnophobia.⁸⁰

IN OT Affects Social Cognition and Behavior

Meta-analytic findings have shown that IN OT improves facial affect recognition.⁸¹ IN OT is also associated with increased prosocial behavior,⁸² including increases in positive communication⁸³ and trust,⁸⁴ though the validity of these latter results have been challenged.⁸⁵ IN OT has also been linked to increased willingness to share emotions related to a painful memory,⁸⁶ increased recall of positive social affiliation memories,⁸⁷ and indicators of pair bonding and relationship outcomes.⁸⁸ In a recent study, participants currently in a romantic relationship recalled fewer memories of previous partners following IN OT versus placebo, and participants who recalled more conflict memories of their current partner after IN OT administration were more likely to have ended their relationship by 18-month follow-up.⁸⁸

However, IN OT appears to enhance both adaptive and maladaptive approach behavior.⁸⁹ For example, IN OT was found to be associated with increased approach toward angry faces,⁹⁰ increased inclinations toward intimate partner violence in trait aggressive individuals,⁹¹ increased aggressive behavior,⁹² and increased envy and gloating.⁹³ IN OT is proposed to enhance socially salient cues, with salience informed by baseline individual differences,^{94,95} which may explain these findings, as well as decreased trust and cooperation behavior among individuals to whom social cues regarding abandonment and trust are highly salient (i.e., with borderline personality disorder).⁹⁶ Mixed findings may also be due in part to use of stimuli that conflate emotion and social cue processing⁹⁷; social stimuli are inherently ambiguous, and can be a sign of both safety and direct (anger faces) and indirect danger (fear faces).

Neurobiological Mechanisms

IN OT may exert its behavioral effects via a number of interacting neurobiological mechanisms that also interact with stressor-elicited biological and psychological responses.

Salience Network

The brain's salience network, which comprises the amygdala, anterior insula, and dorsal anterior cingulate cortex, is a target circuit for OT. The salience network is responsible for identification of the most relevant information from the environment to guide behavior,⁹⁸ and as previously noted, IN OT effects on salience processing may explain the seemingly contradictory findings for effects of IN OT on emotional processes.⁹⁵ A recent positron emission tomography (PET) study revealed that IN OT increased 5-HT_{1A} receptor binding potential in the amygdala/hippocampal complex, insula, dorsal raphe nucleus, and orbitofrontal cortex,⁶⁹ suggesting a possible therapeutic target for stress-related disorders. While a systematic review revealed small effects of IN OT on the amygdala, voxel-based meta-analytic findings based on 11 placebo-controlled imaging studies indicated no direct effects of IN OT on the amygdala.⁹⁹ Null findings may have been due to variability in task type (i.e., implicit vs. explicit stimuli presentation), nature of analysis (i.e., whole-brain versus region-of-interest or small volume correction), participant sex, and widespread effects of IN OT in other brain areas.⁹⁹ Further, heterogeneous findings concerning OT effects on amygdala responses may be due to differential effects on amygdala subregions¹⁰⁰; high-resolution functional magnetic resonance imaging could be useful for elucidating region-specific OT effects. IN OT effects on the left insula and temporal lobes, however, were shown to be consistent across task types and participant sex. IN OT may promote plasticity in salience network brain regions that mediate sensitivity to environmental cues, particularly social cues. Increasing the salience of social cues in different contexts may have different implications for emotional and social well-being.⁹⁴ In positive social contexts, IN OT may be beneficial for remediating stress-related psychiatric symptoms, but in negative contexts, IN OT may exacerbate sensitivity to negative cues and increase these difficulties (see Figure 1).

Neurotransmitters

IN OT-related neural activity in the salience network is mediated by neurotransmitter activity, with evidence for OT effects on the dopamine (DA),¹⁰¹ serotonin,^{41,102} and norepinephrine systems.⁴¹ IN OT may enhance reward salience and reduce fear and anxiety via actions on DA neural circuits.^{101,103} OT appears to promote rewarding effects of social interactions via impact on dopaminergic activity within mesocorticolimbic circuitry, including the PFC and nucleus accumbens,¹⁰⁴ within which OT receptor density is particularly high.⁷⁰

HPA Axis

Dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis is associated with stress-related disorders,¹⁰⁵ with cortisol, a steroidal hormone, attracting the most empirical attention in human subjects research. Both reduced and elevated levels of cortisol have been observed in psychiatric populations, in part due to methodological heterogeneity.^{106,107} A

meta-analysis of 18 randomized, placebo-controlled IN OT studies revealed a modest, nonsignificant effect size for effects of IN OT on cortisol levels.¹⁰⁸ While IN OT did not lower post-task cortisol concentrations, it attenuated release of cortisol during lab tasks, particularly lab challenge tasks known to robustly stimulate the HPA axis (e.g., TSST). The IN OT effect was larger among clinical populations, including those with MDD and borderline personality disorder [Hedges $g = 0.74$, 95% CI $(-1.41, -0.08)$], suggesting possible utility of IN OT for dampening stress responses among individuals with stress-related disorders. However, in these studies, acute stress-induced cortisol may have promoted release of endogenous OT, complicating conclusions about direct effects of IN OT. This point is not unique to cortisol; most studies have not been able to parse direct effects of IN OT from indirect effects on other neurotransmitter or neurohormone systems that may mediate reduced stress hormone reactivity.

Inflammation

Burgeoning research suggests that IN OT has anti-inflammatory effects, which is highly promising for stress-related disorders given evidence of elevated pro-inflammatory cytokine levels in patients with MDD¹⁰⁹ and PTSD.¹¹⁰ Intravenous OT has been shown to attenuate cytokine responses in healthy men.¹¹¹ In animals, OT facilitated wound healing among isolated hamsters, whereas administration of an OT antagonist delayed healing among socially housed animals.¹¹² These findings suggest that IN OT administered after stressful events could reduce inflammation and subsequent risk of developing stress-related disorders.

Treatment Opportunities

IN OT has been proposed as a potential pharmacological agent for the prevention and treatment of PTSD,^{113,114} MDD,^{41,115} and other psychiatric disorders, with several promising reviews and commentaries published in the past few years.^{24,116–118}

IN OT as a Prophylactic Agent

IN OT-enhanced trust and social support seeking could promote adaptive social coping methods to preclude development of stress-related disorders. To our knowledge, however, there are no published studies examining IN OT as a prophylactic for MDD, though recruitment for such studies is ongoing (see clinicaltrials.gov). With respect to trauma, after the baseline visit of a randomized clinical trial testing the effects of 40 IU of twice-daily OT on the development of symptoms of PTSD among emergency department patients within two weeks of trauma, a single dose of IN OT was shown to increase amygdala reactivity to fearful faces,¹¹⁹ and, in response to trauma reminders, reduced amygdala-ventromedial PFC connectivity and increased amygdala–insula functional connectivity.¹²⁰ This is potentially due to increased salience of fear stimuli during the sensitive post-trauma recovery period.^{121,122} However, effects of single versus repeated administration appear to differ, with repeated IN OT administration potentially required to achieve clinically significant effects among high-risk individuals. Specifically, in this same sample, individuals who reported high acute PTSD symptoms had significantly lower PTSD symptoms severity at six month follow-up than individuals treated with placebo.¹²³

IN OT-Enhanced Psychotherapy

While evidence-based psychotherapies and antidepressant treatments for stress-related disorders have meaningful effects, some of which may actually be mediated by effects on OT,¹²⁴ treatments could be improved regarding reduction of side effects, facilitation of more rapid response, and the percentage of individuals who reach and maintain symptom recovery.^{125,126} IN OT could thus serve multiple functions that enhance outcomes for psychotherapies for stress-related disorders, including reducing exaggerated fear, facilitating fear extinction, increasing reward salience of social cues, and promoting therapeutic alliance.¹¹⁴ However, most existing IN OT studies have been single-dose investigations of IN OT as a pharmacological probe in healthy samples of primarily men, thus compromising generalizability to clinical populations, to women (who may require different dosing than men, and who are at increased risk of MDD, PTSD, and comorbid anxiety disorders¹²⁷); and to typical courses of multidose pharmacological treatment. Doses of 20–24 international units (IU) have shown the strongest effects, whereas lower (10 IU) and higher (48 IU) doses show blunted effects,^{128–130} the latter potentially due to excess OT binding to AVP receptors.¹⁹

Major Depressive Disorder

While a single dose of IN OT facilitated flexible shifting of attention away from sad faces in healthy controls,¹³¹ IN OT enhanced processing of sad faces in depressed individuals,¹³² perhaps due to stimulus salience. Similarly, under IN OT, postnatally depressed mothers were sadder and more often described their babies as difficult, but reported that quality of relationship with infant was more positive.¹³³ IN OT was associated with slower attributions in an emotion recognition task among patients with MDD, with accompanying enhanced neural activation within the superior frontal gyrus and insula, suggesting enhanced neural representation of affective states.¹³⁴ These effects may be mediated by OT's effects on empathy, which is elevated in MDD¹³⁵; OT-facilitated empathy may be helpful for healthy individuals, but harmful for individuals already experiencing difficulty regulating sad mood. Severity and course of MDD may also be meaningful qualifiers for use of IN OT. In an open trial without a placebo control group, chronically depressed patients who had not responded to an eight-week trial of 40 mg of escitalopram were given 16 IU of IN OT (in addition to continued escitalopram) for four weeks and reported subsequent increases in life enjoyment and satisfaction.¹³⁶ In a recent study of chronically depressed patients, IN OT reduced attention to angry faces and increased attention toward happy faces, specifically under conditions of heightened awareness,¹³⁷ suggesting that IN OT may be useful for improving social interactions in chronic MDD.

Only one study has examined IN OT within a psychotherapy context for MDD, with anxiogenic effects. MacDonald and colleagues¹¹⁵ administered 40 IU IN OT or placebo to 17 male outpatients with MDD before a videorecorded session with a therapist. Subjective anxiety increased over the course of the session, potentially due to the combination of IN OT-related increase in motivation to affiliate (indicated by reduction in social avoidance/looking away) with a subsequent lack of warmth from the therapist.¹³⁸ IN OT also improved performance on a theory of mind task.¹⁵ Taken together, these results suggest that IN OT may enhance processing of affective cues and reduce subtle behavioral avoidance that can

interfere with affiliation, suggesting that it may be useful for subsets of severely depressed individuals experiencing emotional numbing and deficits in social connection. However, IN OT may be contraindicated in depressed individuals with pre-existing sensitivity to social cues or difficulties managing strong emotions.

Posttraumatic Stress Disorder

While there are currently no published studies of IN OT-enhanced psychotherapy for PTSD, single-dose studies with PTSD samples are promising. In a pilot study of 18 individuals with PTSD, IN OT decreased PTSD symptoms, improved mood, and increased desire for social interaction.¹³⁹ Trend-level reductions in physiological responses to combat imagery were observed in a study of Vietnam-era veterans with PTSD; however, IN OT did not increase responses to pleasant images.¹⁴⁰ Among police officers with PTSD, IN OT dampened amygdala activity to emotional faces, regardless of valence,¹⁴¹ normalized amygdala functional connectivity,¹⁴² increased striatal, dorsal anterior cingulate, and insula responses to monetary reward,¹⁴³ and normalized left anterior insula responses to social reward, while also increasing responses in the right putamen.⁶⁴ Additional studies of the effects of IN OT on threat perception in PTSD samples are needed, given its role in the development and maintenance of PTSD,¹⁴⁴ OT-related increases in salience processing,⁹⁴ and evidence that IN OT *increases* anxiety to unpredictable threat.¹⁴⁵ IN OT may also have distinct effects at different stages of information processing—for example, evidence from a single-dose fear conditioning study suggested that during extinction training, IN OT may first enhance threat perception (indicated by increased electrodermal responses and PFC signals to conditioned fear in the early phase of extinction) before reducing fear during late-phase extinction to levels lower than those observed under placebo.⁷²

Moderating Factors

Observations of null and inconsistent main effects of IN OT led to the recognition that OT effects, like those of many pharmacologies, are often moderated by characteristics of the individuals to whom IN OT is administered, as well as the context in which the medication is administered.⁹⁵

Participant Sex

While some studies have shown that men and women do not differ with respect to basal OT levels,¹⁴⁶ or even that men have higher OT levels than women,¹⁴⁷ it has been proposed that OT may be more biologically relevant to women,³² who, as some studies have shown, have higher levels of circulating OT than men.¹⁴⁸ Observed higher OT levels in women are likely due to gonadal steroids like estrogen,¹⁴⁹ which upregulates central release of OT and the expression of the OT receptor in the brain.^{150,151} Levels of estradiol vary across the menstrual cycle, presumably increasing responsivity to IN OT throughout the cycle. Sex-specific effects of IN OT have been observed across domains, including resting-state functional connectivity,¹⁵² responses to social stress,¹⁵³ empathy,¹⁵⁴ responses to interactive social games,¹⁵⁵ salience of social attributes,¹⁵⁶ and changes in anxiety.¹⁵⁷ A study of a three-week course of daily IN OT administration showed significant decreases in anxiety scores in men but *increases* in anxiety among women.¹⁵⁷ IN OT was also shown to *increase*

amygdala reactivity compared with placebo in response to negative emotional stimuli in healthy women,^{158,159} and to increase amygdala –medial PFC connectivity during rest in young women, but not older women or men of any age.¹⁵² Another study found sex-specific patterns of functional connectivity in PTSD patients that were normalized with one-dose IN OT administration in both men and women.¹⁴² Other studies have not revealed sex differences,^{160,161} potentially due in part to investigators not controlling for natural variation in estrogen levels across the menstrual cycle.¹⁶¹ Sexually dimorphic effects of IN OT may be due to evolutionary-based adaptive values^{75,162}; among men, reduced fear of social threat may be beneficial for successfully competing with other men (mediated by decreases in amygdala reactivity), whereas among women, increased sensitivity and a high level of fear of social threats may help them avoid danger, maintain social ties (including relationships that are valued but at risk),³² and secure offspring survival against predators via defensive aggression (mediated by increases in amygdala reactivity).¹⁶²

Childhood Adverse Events and Attachment Security

Childhood abuse and neglect are associated with elevated risk for MDD¹⁶³ and PTSD.¹⁶⁴ Early caregiving experiences may influence working models and subsequent perception of others as either a source of threat or safety,¹⁶⁵ processes which are then enhanced and reinforced by IN OT via effects on salience processing. Early maltreatment has been associated with lower CSF OT levels,¹⁶⁶ reductions in social support coping behaviors that could stimulate endogenous OT activity,¹⁶ and dulled or reversed effects of IN OT. For example, early life stress was associated with increased cortisol responses and limbic deactivation after IN OT.¹⁶⁷ Among men with a history of early parental separation compared with controls, IN OT attenuated cortisol decreases.¹⁶⁸ Compared with controls, IN OT did not affect use of excessive force during listening to infant cries among women who experienced harsh parental discipline.¹⁶⁹ Similarly, anxiously attached individuals remembered their mothers as less caring and close following OT versus placebo, compared with securely attached individuals, who remembered their mothers as more caring and close in childhood following IN OT versus placebo.¹⁷⁰

Alternatively, some studies suggest utility of IN OT among individuals with childhood adversity. IN OT-related improvements in social cognition and corresponding neural activation in the insula and superior temporal gyrus were *only* observed in women reporting higher levels of maternal love withdrawal.¹⁷¹ IN OT induced a negative shift in TSST-induced functional connectivity between the amygdala and hippocampus in participants with higher levels of emotional abuse; findings were reversed in individuals with low emotional abuse.¹⁷² IN OT increased levels of attachment in the majority of men classified as having insecure attachments,¹⁷³ and avoidantly attached individuals showed greater increases in self-perceptions of being communal after IN OT than other participants.¹⁷⁴ IN OT increased cooperation and trust in healthy men who scored high on attachment avoidance, but not among men with high attachment anxiety.¹⁷⁵ Studies of resting state connectivity¹⁷⁶ and cortisol levels¹⁶⁸ suggest that childhood experiences moderate IN OT effects even in the absence of social stimuli, suggesting that childhood adversity fundamentally affects the oxytocinergic system via neurological pathways or methylation of the oxytocin receptor gene (*OXTR*).

Genetic and Epigenetic Variability

IN OT leads to variations in the final active concentration of OT in the brain, but effects are dependent on OT receptor density in critical brain regions, which is influenced by genetic variability in *OXTR*. OT receptor expression is also highly regulated by the methylation of its coding gene, which in turn is influenced by numerous factors.¹⁷⁷ Accumulating research suggests an association between stress-related behavioral phenotypes and *OXTR* single nucleotide polymorphisms (SNPs).¹⁷⁸ *OXTR* SNPs linked to environmental sensitivity may interact with early-life adverse events to increase risk for stress-related disorders^{179,180} or could serve as bio-markers for therapeutic IN OT effects.

The *OXTR* rs53576 SNP (minor allele: A, major allele: G) has gained the most attention to date. Compared with A/A carriers, individuals with G/G and A/G genotypes have been shown to be more likely to seek emotional support when distressed,¹⁸¹ to exhibit higher trust-related behaviors,¹⁸² and to more greatly benefit from social support.¹⁸³ Specifically, male G allele carriers have been found to have less pronounced cortisol responses to the TSST after *in vivo* social support than A/A carriers.¹⁸³ The A allele has also been found to be linked to morphometric alterations of the hypothalamus and amygdala, which were in turn associated with increased functional connectivity between these structures during processing of emotionally salient social cues.¹⁸⁴ This variant may function to modulate risk for psychopathology via influence on limbic system reactivity to social cues. However, a recent study found no effect between rs53576 and depressive symptoms among undergraduate students, but did find that the A/A genotype of a SNP on the CD38 gene that controls OT release was associated with feelings of alienation from parents and peers and increased levels of suicidal ideation.¹⁸⁵ Studies using genome-wide association, polygenic, and gene-by-environment approaches; studies identifying the functional consequences of genetic variation in *OXTR*; and studies of associations between stress-related disorders and *OXTR* signaling pathways, *OXTR* molecular cascades, and interactions between the OT system and other neurotransmitters are needed.

Dispositional Traits and Skills

Finally, with respect to individual differences, OT effects have been shown to differ as a function of dispositional traits and skills. For example, effects of IN OT were shown to be moderated by emotion regulation abilities, with individuals with poorer (vs. better) emotion regulation abilities showing reduced cortisol response to stress after IN OT.¹⁸⁶ IN OT has predicted greater perceived social connection, more positive responses to help, and greater trust, but only for individuals low in extraversion.¹⁸⁷ Several studies have also shown that autistic-like traits moderate OT effects, though the direction of effects vary. For example, among individuals with greater autistic traits (i.e., poorer social cognitive skills), IN OT has shown both stronger social effects, including improved empathic accuracy¹⁸⁸ and attention toward positive faces,¹⁸⁹ as well as blunted effects on perceived hedonic value of interpersonal touch¹⁹⁰ and reversed effects on consumers' relationships with brands.¹⁹¹

Context of IN OT Administration

IN OT administered in a competitive, threatening, or affiliative context has varied effects. IN OT promoted increased cooperation and trust toward in-group members in a financial

decision-making game, but increased defensive behaviors toward competing out-group members.¹⁹² IN OT also reduced cooperation in men by enhancing fear, suggesting that OT promotes fear and distrust of unfamiliar individuals.¹⁹³ Safe social support may need to be available for IN OT to exert its full anxiolytic effects,¹⁹⁴ and similarly, the lack of social support may impede effects. During recall of negative autobiographical memories, among women but not men, IN OT decreased perceived emotional support.¹⁹⁵ This effect was stronger among women motivated to affiliate with the experimenter and reversed among women who received social contact from the experimenter. Further, single- and multiple-dose studies may differentially interact with context; it is possible that, in a multidose treatment context, if a patient does not feel increasingly safe with the clinician over time, IN OT could enhance these concerns and impede treatment response. Alternatively, it may be more critical for the patient to feel safe *before* administering IN OT for it to have beneficial effects.

Clinical Applications and Future Directions

Existing evidence suggests that IN OT pharmacotherapy could be part of strategic and targeted therapeutic approaches. IN OT could be administered to individuals identified as having dysregulated OT system activity via the Regensburg Oxytocin Challenge, which characterizes OT system responsiveness to a variety of challenges.²⁹ IN OT could be combined with psychosocial interventions that target specific cognitive or behavioral outcomes or features of stress-related disorders that may be responsive to IN OT. For example, depressed patients with comorbid anxiety symptoms and low levels of social attachment¹⁰² and individuals for whom stressors involve negative social interactions or in which social isolation is the presenting problem may be good candidates. As an adjunct to time-limited psychotherapy, IN OT may be most effective when used at therapeutic dosage in the context of a warm, supportive clinician to target specific social learning (e.g., perspective-taking in interpersonal psychotherapy or cognitive reappraisal in cognitive-behavioral therapy) and cognitive processes (e.g., preferential attention to negative faces, attentional avoidance of facial expressions). Alternatively, providers could promote behaviors that stimulate the endogenous OT system, such as social support interventions. Evidence for the roles of attachment and childhood adversity on the effects of IN OT in clinical populations is sparse, and would inform personalized approaches to treatment; for example, IN OT may be beneficial for individuals with dismissive attachment (i.e., high avoidance and low anxiety) but contraindicated for individuals with more fearful attachment (high avoidance and high anxiety).⁹⁶

Clinical trials of IN OT with demonstration of target engagement (i.e., demonstrated activation of a proposed therapeutic mechanism at a clinically effective dose) are needed.¹⁹⁶ In addition, given publication bias of positive IN OT findings,¹⁹⁷ poor reproducibility of effects,¹⁹⁸ and retractions of seemingly promising meta-analytic findings,^{199,200} caution in recommending IN OT for patients with stress-related disorders is warranted. Improved research standards including increased statistical power and reporting on trials without expected results are needed before IN OT can be utilized as a first-line treatment for stress-related disorders.²⁰¹

Conclusions

As IN OT enhances affiliation, reward salience, and emotion regulation at both the behavioral and neural levels, it may promote natural recovery from traumatic and chronic stress, mitigating risk of stress-related disorders, as well as facilitate symptom reduction in the context of psychotherapy. IN OT appears to act on a number of neurobiological systems relevant to stress-related disorders, including the HPA axis, limbic system, neurotransmitters, and immune functioning. Despite the proliferation of IN OT studies in the past two decades, our understanding of the therapeutic value of IN OT remains limited in ways that are meaningful to the application of IN OT to stress-related disorders. IN OT does not have uniform effects on all individuals. The potential for sexually dimorphic effects of IN OT and evidence of sex-specific responses to stress necessitate examination of sex as a biological variable in IN OT studies. Further, given evidence that hormone levels, menstrual phase, and hormonal contraceptive status influence OT levels²⁰² and psychiatric symptoms (including PTSD),²⁰³ concerted efforts to measure or monitor these factors are needed to make accurate conclusions about the potential therapeutic role of IN OT for women with stress-related disorders. Examination of biomarkers of adaptive responses to IN OT is needed, including those related to childhood adversity, as developmentally informed interpretation of social cues as “safe” may promote prosociality but interpretation of cues as “unsafe” may promote defensive, potentially maladaptive emotions and behaviors.³⁷ Examination of moderators of response to IN OT will contribute to development of strategic, targeted, sex-specific, and developmentally sensitive IN OT treatment approaches for stress-related disorders, in which increasing the salience of social and emotional cues may improve, maintain, or worsen social cognition and behavior, depending on current context and/or the patient to whom the IN OT is administered.

Acknowledgments

Dr Sippel is now affiliated with the National Center for PTSD Executive Division, VA Medical Center, White River Junction, VT, USA.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The writing of this manuscript was supported by the Department of Veterans Affairs, Veterans Health Administration, VISN 1 Career Development Award to Lauren M. Sippel. The views and opinions expressed in this report are those of the authors and should not be construed to represent the U.S. government.

References

1. Olf M, Langeland W, Gersons BP. The psychobiology of PTSD: coping with trauma. *Psychoneuroendocrinology*. 2005; 30:974–982.
2. Olf M, Langeland W, Gersons BP. Effects of appraisal and coping on the neuroendocrine response to extreme stress. *Neurosci Biobehav Rev*. 2005; 29:457–467. [PubMed: 15820550]
3. Sandi C, Haller J. Stress and the social brain: behavioural effects and neurobiological mechanisms. *Nat Rev Neurosci*. 2015; 16:290–304. [PubMed: 25891510]
4. American Psychiatric Association. *Diagnostic and statistical manual of mental disorders*. 5. Washington, DC: American Psychiatric Association; 2013.
5. Gold PW. The organization of the stress system and its dysregulation in depressive illness. *Mol Psychiatr*. 2015; 20:32–47.

6. Tsai J, Pietrzak RH, Southwick SM, et al. Examining the dimensionality of combat-related posttraumatic stress and depressive symptoms symptoms in treatment-seeking OEF/OIF/OND veterans. *J Affect Disord.* 2011; 135:310–314. [PubMed: 21782249]
7. Pizzagalli DA. Depression, stress, and anhedonia: toward a synthesis and integrated model. *Annu Rev Clin Psychol.* 2014; 10:393–423. [PubMed: 24471371]
8. Nawijn L, van Zuiden M, Frijling JL, et al. Reward functioning in PTSD: a systematic review exploring the mechanisms underlying anhedonia. *Neurosci Biobehav Rev.* 2015; 51:189–204. [PubMed: 25639225]
9. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. *Psychol Bull.* 2014; 140:774–815. [PubMed: 24417575]
10. Zoladz, PR., Diamond, D. Psychosocial predator stress model of PTSD based on clinically relevant risk factors for trauma-induced psychopathology. In: Bremner, JD., editor. *Posttraumatic stress disorder: From neurobiology to treatment.* Hoboken, NJ: John Wiley & Sons, Inc; 2016.
11. Goenjian AK, Steinberg AM, Najarian LM, et al. Prospective study of posttraumatic stress, anxiety, and depressive reactions after earthquake and political violence. *Am J Psychiatry.* 2000; 157:911–916. [PubMed: 10831470]
12. Pietrzak RH, Johnson DC, Goldstein MB, et al. Psychosocial buffers of traumatic stress, depressive symptoms, and psychosocial difficulties in veterans of Operations Enduring Freedom and Iraqi Freedom: The role of resilience, unit support, and postdeployment social support. *J Affect Disord.* 2010; 120:188–192. [PubMed: 19443043]
13. Hofmann SG, Litz BT, Weathers FW. Social anxiety, depression, and PTSD in Vietnam veterans. *J Anxiety Disord.* 2003; 17:573–582. [PubMed: 12941367]
14. Macias CM, Young R, Barreira P. Loss of trust: correlates of the comorbidity of PTSD and severe mental illness. *J Loss Trauma.* 2000; 5:103–123.
15. Mikulincer M, Shaver PR. An attachment perspective on psychopathology. *World Psychiatry.* 2012; 11:11–15. [PubMed: 22294997]
16. Olf M. Bonding after trauma: on the role of social support and the oxytocin system in traumatic stress. *Eur J Psychotraumatol.* 2012; 3:18597.
17. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. *Physiol Rev.* 2001; 81:629–683. [PubMed: 11274341]
18. Neumann ID, Slattery DA. Oxytocin in general anxiety and social fear: a translational approach. *Biol Psychiat.* 2016; 79:213–221. [PubMed: 26208744]
19. Burbach, JP., Young, LJ., Russell, J. Oxytocin: synthesis, secretion and reproductive functions. In: Neill, JD., editor. *Knobil and Neill's physiology of reproduction.* 3. New York, NY: Elsevier; 2006.
20. Neumann ID, Landgraf R. Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors. *Trends Neurosci.* 2012; 35:649–659. [PubMed: 22974560]
21. Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. *Am J Psychiat.* 2010; 167:748–751. [PubMed: 20595427]
22. Macdonald K, Feifel D. Oxytocin's role in anxiety: a critical appraisal. *Brain Res.* 2014; 1580:22–56. [PubMed: 24468203]
23. Veening JG, Olivier B. Intranasal administration of oxytocin: behavioral and clinical effects, a review. *Neurosci Biobehav Rev.* 2013; 37:1445–1465. [PubMed: 23648680]
24. Macdonald K, Feifel D. Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders. *Frontiers in Neuroscience.* 2013; 7:35. [PubMed: 23508240]
25. Leng G, Ludwig M. Intranasal oxytocin: myths and delusions. *Biol Psychiatry.* 2016; 79:243–250. [PubMed: 26049207]
26. Wotjak CT, Ganster J, Kohl G, et al. Dissociated central and peripheral release of vasopressin, but not oxytocin, in response to repeated swim stress: new insights into the secretory capacities of peptidergic neurons. *Neuroscience.* 1998; 85:1209–1222. [PubMed: 9681958]
27. Knobloch HS, Charlet A, Hoffmann LC, et al. Evoked axonal oxytocin release in the central amygdala attenuates fear response. *Neuron.* 2012; 73:553–566. [PubMed: 22325206]

28. Engert V, Koester AM, Riepenhausen A, et al. Boosting recovery rather than buffering reactivity: higher stress-induced oxytocin secretion is associated with increased cortisol reactivity and faster vagal recovery after acute psychosocial stress. *Psychoneuroendocrinology*. 2016; 74:111–120. [PubMed: 27608360]
29. Jong TR, Menon R, Bludau A, et al. Salivary oxytocin concentrations in response to running, sexual self-stimulation, breastfeeding and the TSST: The Regensburg Oxytocin Challenge (ROC) study. *Psychoneuroendocrinology*. 2015; 62:381–388. [PubMed: 26385109]
30. Holt-Lunstad J, Birmingham WA, Light KC. Influence of a “warm touch” support enhancement intervention among married couples on ambulatory blood pressure oxytocin alpha amylase and cortisol. *Psychosom Med*. 2008; 70:976–985. [PubMed: 18842740]
31. Tabak BA, McCullough ME, Szeto A, et al. Oxytocin indexes relational distress following interpersonal harms in women. *Psychoneuroendocrinology*. 2010; 36:115–122. [PubMed: 20688437]
32. Taylor SE. Tend and befriend: biobehavioral bases of affiliation under stress. *Current Directions in Psychological Science*. 2006; 15:273–277.
33. Grewen KM, Light KC. Plasma oxytocin is related to lower cardiovascular and sympathetic reactivity to stress. *Biol Psychol*. 2011; 87:340–349. [PubMed: 21540072]
34. Ditzen B, Neumann ID, Bodenmann G, et al. Effects of different kinds of couple interaction on cortisol and heart rate responses to stress in women. *Psychoneuroendocrinology*. 2007; 32:565–574. [PubMed: 17499441]
35. Smith TW, Uchino BN, MacKenzie J, et al. Effects of couple interactions and relationship quality on plasma oxytocin and cardiovascular reactivity: empirical findings and methodological considerations. *Int J Psychophysiol*. 2013; 88:271–281. [PubMed: 22543270]
36. Seng J, Miller J, Sperlrich M, et al. Exploring dissociation and oxytocin as pathways between trauma exposure and trauma-related hyperemesis gravidarum: a test-of-concept pilot. *J Trauma Dissociation*. 2013; 1:40–55.
37. Frijling JL, van Zuiden M, Nawijn L, et al. Salivary oxytocin and vasopressin levels in police officers with and without post-traumatic stress disorder. *J Neuroendocrinol*. 2015; 27:743–751. [PubMed: 26184739]
38. Olf M, Frijling JL, Kubzansky LD, et al. The role of oxytocin in social bonding, stress regulation and mental health: an update on the moderating effects of context and inter-individual differences. *Psychoneuroendocrinology*. 2013; 38:1883–1894. [PubMed: 23856187]
39. Massey SH, Backes KA, Schuette SA. Plasma oxytocin concentration and depressive symptoms: a review of current evidence and directions for future research. *Depress Anxiety*. 2016; 33:1–7.
40. Rutigliano G, Rocchetti M, Paloyelis Y, et al. Peripheral oxytocin and vasopressin: biomarkers of psychiatric disorders? A comprehensive systematic review and preliminary meta-analysis. *Psychiatry Res*. 2016; 241:207–220. [PubMed: 27183106]
41. McQuaid RJ, McInnis OA, Abizaid A, et al. Making room for oxytocin in understanding depression. *Neurosci Biobehav Rev*. 2014; 45:305–322. [PubMed: 25025656]
42. McCullough ME, Churchland PS, Mendez AJ. Problems with measuring peripheral oxytocin: can the data on oxytocin and human behavior be trusted? *Neurosci Biobehav Rev*. 2013; 37:1285–1492.
43. Leng G, Sabatier N. Measuring oxytocin and vasopressin: bioassays, immunoassays and random numbers. *J Neuroendocrinol*. Epub ahead of print 28 Jul 2016.
44. MacDonald E, Dadds MR, Brennan JL, et al. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. *Psychoneuroendocrinology*. 2011; 36:1114–1126. [PubMed: 21429671]
45. Neumann ID, Maloumy R, Beiderbeck DI, et al. Increased brain and plasma oxytocin after nasal and peripheral administration in rats and mice. *Psychoneuroendocrinology*. 2013; 38:1985–1993. [PubMed: 23579082]
46. Rault JL. Effects of positive and negative human contacts and intranasal oxytocin on cerebrospinal fluid oxytocin. *Psychoneuroendocrinology*. 2016; 69:60–66. [PubMed: 27032064]

47. Quintana DS, Alvares GA, Hickie IB, et al. Do delivery routes of intranasally administered oxytocin account for observed effects on social cognition and behavior? A two-level model. *Neurosci Biobehav Rev.* 2015; 49:182–192. [PubMed: 25526824]
48. Quintana DS, Westlve LT, Alnæs D, et al. Low dose intra-nasal oxytocin delivered with Breath Powered device dampens amygdala response to emotional stimuli: a peripheral effect-controlled within-subjects randomized dose-response fMRI trial. *Psychoneuroendocrinology.* 2016; 69:180–188. [PubMed: 27107209]
49. Modi ME, Connor-Stroud F, Landgraf R. Aerosolized oxytocin increases cerebrospinal fluid oxytocin in rhesus macaques. *Psychoneuroendocrinology.* 2014; 45:49–57. [PubMed: 24845176]
50. Guastella AJ, Hickie IB, McGuinness MM, et al. Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research. *Psychoneuroendocrinology.* 2013; 38:612–625. [PubMed: 23265311]
51. Bogdan R, Pizzagalli DA. Acute stress reduces hedonic capacity: implications for depression. *Biol Psychiatry.* 2006; 60:1147–1154. [PubMed: 16806107]
52. Esher N, Roiser J. Reward and punishment processing in depression. *Biol Psychiatry.* 2010; 68:118–124. [PubMed: 20303067]
53. Peckham AD, McHugh RK, Otto MW. A meta-analysis of the magnitude of biased attention in depression. *Depress Anxiety.* 2010; 27:1135–1142. [PubMed: 21049527]
54. Harari-Dahan O, Bernstein A. A general approach-avoidance hypothesis of oxytocin: accounting for social and non-social effects of oxytocin. *Neurosci Biobehav Rev.* 2014; 47:506–519. [PubMed: 25454355]
55. Groppe SE, Gossen A, Rademacher L, et al. Oxytocin influences processing of socially relevant cues in the ventral tegmental area of the human brain. *Biol Psychiatry.* 2013; 74:172–179. [PubMed: 23419544]
56. Scheele D, Wille A, Kendrick KM, et al. Oxytocin enhances brain reward system responses in men viewing the face of their female partner. *Proc Natl Acad Sci USA.* 2013; 110:20308–20313. [PubMed: 24277856]
57. Striepens N, Matusch A, Kendrick KM, et al. Oxytocin enhances attractiveness of unfamiliar female faces independent of the dopamine reward system. *Psychoneuroendocrinology.* 2014; 39:74–87. [PubMed: 24275006]
58. Schulze L, Lischke A, Greif J, et al. Oxytocin increases recognition of masked emotional faces. *Psychoneuroendocrinology.* 2011; 36:1378–1382. [PubMed: 21477929]
59. Di Simplicio M, Massey-Chase R, Cowen PJ, et al. Oxytocin enhances processing of positive versus negative emotional information in healthy male volunteers. *J Psychopharmacol.* 2009; 23(3):241–248. [PubMed: 18801829]
60. Preckel K, Scheele D, Kendrick KM, et al. Oxytocin facilitates social approach behavior in women. *Front Behav Neurosci.* 2014; 8:191. [PubMed: 24904342]
61. Scheele D, Striepens N, Güntürkün O, et al. Oxytocin modulates social distance between males and females. *J Neurosci.* 2012; 32:16074–16079. [PubMed: 23152592]
62. Guastella AJ, Carson DS, Dadds MR, et al. Does oxytocin influence the early detection of angry and happy faces? *Psychoneuroendocrinology.* 2009; 34:220–225. [PubMed: 18848401]
63. Fischer-Shofty M, Shamay-Tsoory SG, Harari H, et al. The effect of intranasal administration of oxytocin on fear recognition. *Neuropsychologia.* 2010; 48:179–184. [PubMed: 19747930]
64. Nawijn L, van Zuiden M, Koch SBJ, et al. Intranasal oxytocin increases neural responses to social reward in post-traumatic stress disorder. *Soc Cogn Affect Neurosci.* Epub ahead of print 10 September 2016.
65. Flanagan JC, Baker NL, McRae-Clark AL, et al. Effects of adverse childhood experiences on the association between intranasal oxytocin and social stress reactivity among individuals with cocaine dependence. *Psychiatry Res.* 2015; 229:94–100. [PubMed: 26231584]
66. de Oliveira DC, Zuardi AW, Graeff FG, et al. Anxiolytic-like effect of oxytocin in the simulated public speaking test. *J Psychopharmacol.* 2012; 26:497–504. [PubMed: 21555332]
67. Linnen AM, Ellenbogen MA, Cardoso C, et al. Intranasal oxytocin and salivary cortisol concentrations during social rejection in university students. *Stress.* 2012; 15:393–402. [PubMed: 22044077]

68. Gaffey A, Wirth M. Oxytocin increases cortisol in men exposed to acute social-evaluative stress. *Psychoneuroendocrinology*. 2015; 61:74–75.
69. Mottolese R, Redoutè J, Costes N, et al. Switching brain serotonin with oxytocin. *Proc Natl Acad Sci USA*. 2014; 111:8637–8642. [PubMed: 24912179]
70. Insel TR, Shapiro LE. Oxytocin receptor distribution reflects social organization in monogamous and polygamous voles. *Proc Natl Acad Sci*. 1992; 89:5981–5985. [PubMed: 1321430]
71. Acheson D, Feifel D, de Wilde S, et al. The effect of intra-nasal oxytocin treatment on conditioned fear extinction and recall in a healthy human sample. *Psychopharmacology*. 2013; 229:199–208. [PubMed: 23644911]
72. Eckstein M, Becker B, Scheele D, et al. Oxytocin facilitates the extinction of conditioned fear in humans. *Biol Psychiat*. 2015; 78:194–202. [PubMed: 25542304]
73. Huber D, Veinante P, Stoop R. Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. *Science*. 2005; 308:245–248. [PubMed: 15821089]
74. Petrovic P, Kalisch R, Singer T, et al. Oxytocin attenuates affective evaluations of conditioned faces and amygdala activity. *J Neurosci*. 2008; 28:6607–6615. [PubMed: 18579733]
75. Ma Y, Shamay-Tsoory S, Han S, et al. Oxytocin and social adaptation: insights from neuroimaging studies of healthy and clinical populations. *Trends Cogn Sci*. 2016; 20:133–145. [PubMed: 26616296]
76. Sripada CS, Phan KL, Labuschagne I, et al. Oxytocin enhances resting-state connectivity between amygdala and medial frontal cortex. *Int J Neuropsychopharmacol*. 2013; 16:255–260. [PubMed: 22647521]
77. Kirsch P, Esslinger C, Chen Q, et al. Oxytocin modulates neural circuitry for social cognition and fear in humans. *J Neurosci*. 2005; 25:11489–11493. [PubMed: 16339042]
78. Eckstein M, Scheele D, Patin A, et al. Oxytocin facilitates Pavlovian fear learning in males. *Neuropsychopharmacol*. 2016; 41:932–939.
79. Striepens N, Scheele D, Kendrick KM, et al. Oxytocin facilitates protective responses to aversive social stimuli in males. *Proc Natl Acad Sci USA*. 2012; 109:18144–18149. [PubMed: 23074247]
80. Acheson DT, Feifel D, Kamenski M, et al. Intranasal oxytocin administration prior to exposure therapy for arachnophobia impedes treatment response. *Depress Anxiety*. 2015; 32:400–407. [PubMed: 25826649]
81. Shahrestani S, Kemp AH, Guastella AJ. The impact of a single administration of intranasal oxytocin on the recognition of basic emotions in humans: a meta-analysis. *Neuropsychopharmacology*. 2013; 38:1929–1936. [PubMed: 23575742]
82. Striepens N, Kendrick KM, Maier W, et al. Prosocial effects of oxytocin and clinical evidence for its therapeutic potential. *Front Neuroendocrin*. 2011; 32:426–450.
83. Ditzen B, Schaer M, Gabriel B, et al. Intranasal oxytocin increases positive communication and reduces cortisol levels during couple conflict. *Biol Psychiatry*. 2009; 65:728–731. [PubMed: 19027101]
84. Baumgartner T, Heinrichs M, Vonlanthen A, et al. Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. *Neuron*. 2008; 58:639–650. [PubMed: 18498743]
85. Nave G, Camerer C, McCullough M. Does oxytocin increase trust in humans? A critical review of research. *Perspect Psychol Sci*. 2015; 10:772–789. [PubMed: 26581735]
86. Lane A, Luminet O, Rimé B, et al. Oxytocin increases willingness to socially share one's emotions. *Int J Psychol*. 2013; 48:676–681. [PubMed: 22554106]
87. Cardoso C, Orlando MA, Brown CA, et al. Oxytocin and enhancement of the positive valence of social affiliation memories: an autobiographical memory study. *Soc Neurosci*. 2014; 9:186–195. [PubMed: 24387003]
88. Cardoso C, Kalogeropoulos C, Brown CA, et al. Memory response to oxytocin predicts relationship dissolution over 18 months. *Psychoneuroendocrinology*. 2016; 68:171–176. [PubMed: 26986091]
89. Kemp AH, Guastella AJ. The role of oxytocin in human affect: a novel hypothesis. *Curr Dir Psychol Sci*. 2011; 20:222–231.

90. Radke S, Roelofs K, de Bruijn ER. Acting on anger: social anxiety modulates approach-avoidance tendencies after oxytocin administration. *Psychol Sci.* 2013; 24:1573–1578. [PubMed: 23737083]
91. DeWall CN, Gillath O, Pressman SD, et al. When the love hormone leads to violence: oxytocin increases intimate partner violence inclinations among high trait aggressive people. *Soc Psychol Person Sci.* 2014; 5:691–697.
92. Ne'eman R, Perach-Barzilay N, Fischer-Shofty M, et al. Intranasal administration of oxytocin increases human aggressive behavior. *Horm Behav.* 2016; 80:125–131. [PubMed: 26862988]
93. Shamay-Tsoory SG, Fischer M, Dvash J. Intranasal administration of oxytocin increases envy and schadenfreude (gloating). *Biol Psychiat.* 2009; 66:864–870. [PubMed: 19640508]
94. Shamay-Tsoory SG, Abu-Akel A. The social salience hypothesis of oxytocin. *Biol Psychiat.* 2016; 79(3):194–202. [PubMed: 26321019]
95. Bartz JA, Zaki J, Bolger N, et al. Social effects of oxytocin in humans: context and person matter. *Trends Cogn Sci.* 2011; 15:301–309. [PubMed: 21696997]
96. Bartz J, Simeon D, Hamilton H, et al. Oxytocin can hinder trust and cooperation in borderline personality disorder. *Soc Cogn Affect Neurosci.* 2010; 6:556–563. [PubMed: 21115541]
97. Di Simplicio M, Harmer CJ. Oxytocin and emotion processing. *J Psychopharmacol.* Epub ahead of print 12 Apr 2016.
98. Seeley WW, Menon V, Schatzberg AF, et al. Dissociable intrinsic connectivity networks for salience processing and executive control. *J Neurosci.* 2007; 27:2349–2356. [PubMed: 17329432]
99. Wigton R, Radua J, Allen P, et al. Neurophysiological effects of acute oxytocin administration: systematic review and meta-analysis of placebo-controlled imaging studies. *J Psychiatr Neurosci.* 2015; 40:E1–E22.
100. Gamer M, Zurowski B, Buchel C. Different amygdala subregions mediate valence-related and attentional effects of oxytocin in humans. *Proc Natl Acad Sci USA.* 2010; 107:9400–9405. [PubMed: 20421469]
101. Love TM. Oxytocin, motivation and the role of dopamine. *Pharmacol Biochem Behav.* 2014; 119:49–60. [PubMed: 23850525]
102. Slattery DA, Neumann ID. Oxytocin and major depression disorder: experimental and clinical evidence for etiology and possible treatment. *Pharmaceuticals.* 2010; 3:702–724. [PubMed: 27713275]
103. Bale AM, Davis AP, Auger DM, et al. CNS region-specific oxytocin receptor expression: importance in regulation of anxiety and sex behavior. *J Neurosci.* 2001; 21:2546–2552. [PubMed: 11264328]
104. Baskerville TA, Douglas AJ. Dopamine and oxytocin interactions underlying behaviors: potential contributions to behavioral disorders. *CNS Neurosci Ther.* 2010; 16:e92–e123. [PubMed: 20557568]
105. Morris MC, Compas BE, Garber J. Relations among posttraumatic stress disorder, comorbid major depression, and HPA function: a systematic review and meta-analysis. *Clin Psychol Rev.* 2012; 32:301–315. [PubMed: 22459791]
106. Olf M, Guzelcan Y, de Vries GJ, et al. HPA- and HPT-axis alterations in chronic posttraumatic stress disorder. *Psychoneuroendocrinology.* 2006; 31:1220–1230. [PubMed: 17081699]
107. Vreeburg SA, Zitman FG, van Pelt J, et al. Salivary cortisol levels in persons with and without different anxiety disorders. *Psychosom Med.* 2010; 72:340–347. [PubMed: 20190128]
108. Cardoso C, Kingdon D, Ellenbogen MA. A meta-analytic review of the impact of oxytocin administration on cortisol concentrations during laboratory tasks: moderation by method and mental health. *Psychoneuroendocrinology.* 2014; 49:161–170. [PubMed: 25086828]
109. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. *Biol Psychiatry.* 2010; 67:446–457. [PubMed: 20015486]
110. Gill JM, Saligan L, Woods S, et al. PTSD is associated with an excess of inflammatory immune activities. *Perspect Psychiatr Care.* 2009; 45:262–277. [PubMed: 19780999]
111. Clodi M, Vila G, Geyeregger R, et al. Oxytocin alleviates the neuroendocrine and cytokine response to bacterial endotoxin in healthy men. *Am J Physiol: Endocrinol Metab.* 2008; 295:E686–E691. [PubMed: 18593851]

112. Detillion CE, Craft TKS, Glasper ER, et al. Social facilitation of wound healing. *Psychoneuroendocrinology*. 2004; 29:1004–1011. [PubMed: 15219651]
113. Koch SB, van Zuiden M, Nawijn L, et al. Intranasal oxytocin as strategy for medication-enhanced psychotherapy of PTSD: salience processing and fear inhibition processes. *Psychoneuroendocrinology*. 2014; 40:242–256. [PubMed: 24485496]
114. Olff M, Langeland W, Witteveen A, et al. A psychobiological rationale for oxytocin in the treatment of posttraumatic stress disorder. *CNS Spectr*. 2010; 15:522–530. [PubMed: 20703199]
115. MacDonald K, MacDonald TM, Brüne M, et al. Oxytocin and psychotherapy: a pilot study of its physiological, behavioral and subjective effects in males with depression. *Psychoneuroendocrinology*. 2013; 38:2831–2843. [PubMed: 23810433]
116. Martinetz S, Neumann ID. The potential of oxytocin as a therapeutic target for psychiatric disorders. *Expert Opin Ther Tar*. 2016; 20:515–518.
117. Cochran DM, Fallon D, Hill M, et al. The role of oxytocin in psychiatric disorders: a review of biological and therapeutic research findings. *Harvard Rev Psychiat*. 2013; 21:219.
118. Bakermans-Kranenburg MJ, van Ijzendoorn MH. Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy. *Transl Psychiatry*. 2013; 3:e258. [PubMed: 23695233]
119. Frijling JL, van Zuiden M, Koch SB, et al. Effects of intranasal oxytocin on amygdala reactivity to emotional faces in recently trauma-exposed individuals. *Soc Cogn Affect Neurosci*. 2016; 11:327–336. [PubMed: 26382634]
120. Frijling JL, van Zuiden M, Koch SB, et al. Intranasal oxytocin affects amygdala functional connectivity after trauma script-driven imagery in distressed recently trauma-exposed individuals. *Neuropsychopharmacology*. 2015; 41:1286–1296. [PubMed: 26346640]
121. Olff M, van Zuiden M, Koch S, et al. Intranasal oxytocin: miracle cure after trauma? *Eur J Psychotraumatol*. 2015; 6:27631.
122. Olff M, Koch SB, Nawijn L, et al. Social support, oxytocin, and PTSD. *Eur J Psychotraumatol*. 2014; 5:26513. [PubMed: 25511718]
123. van Zuiden M, et al. Intranasal oxytocin to prevent PTSD symptoms: a randomized controlled trial in emergency department patients. *Biol Psychiatry*. in press. DOI: <http://dx.doi.org/10.1016/j.biopsych.2016.11.012>
124. Lee R, Garcia F, Van de Kar LD, et al. Plasma oxytocin in response to pharmacological challenge to D-fenfluramine and placebo in healthy men. *Psychiatry Res*. 2003; 118:129–136. [PubMed: 12798977]
125. Bradley R, Greene J, Russ E, et al. A multidimensional meta-analysis of psychotherapy for multidimensional meta-analysis of psychotherapy for PTSD. *Am J Psychiat*. 2005; 162:214–227. [PubMed: 15677582]
126. Zajecka J, Kornstein SG, Blier P. Residual symptoms in major depressive disorder: prevalence, effects, and management. *J Clin Psychiat*. 2013; 74:407–414.
127. Altemus M, Sarvaiya N, Neill Epperson C. Sex differences in anxiety and depression clinical perspectives. *Front Neuroendocrinol*. 2014; 35:320–330. [PubMed: 24887405]
128. Goldman MB, Gomes AM, Carter CS, et al. Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia. *Psychopharmacology (Berl)*. 2011; 216:101–110. [PubMed: 21301811]
129. Hall SS, Lightbody AA, McCarthy BE, et al. Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome. *Psychoneuroendocrinology*. 2012; 37:509–518. [PubMed: 21862226]
130. Cardoso C, Ellenbogen MA, Orlando SL, et al. Intranasal oxytocin attenuates the cortisol response to physical stress: a dose-response study. *Psychoneuroendocrinology*. 2013; 38:399–407. [PubMed: 22889586]
131. Ellenbogen MA, Linnen A, Grumet R, et al. The acute effects of intranasal oxytocin on automatic and effortful attentional shifting to emotional faces. *Psychophysiology*. 2012; 49:128–137. [PubMed: 22092248]

132. Ellenbogen MA, Linnen AM, Cardoso C, et al. Intranasal oxytocin impedes the ability to ignore task-irrelevant facial expressions of sadness in students with depressive symptoms. *Psychoneuroendocrinology*. 2013; 38:387–398. [PubMed: 22902063]
133. Mah BL, van Ijzendoorn MH, Smith R, et al. Oxytocin in postnatally depressed mothers: its influence on mood and expressed emotion. *Prog Neuropsychopharmacol Biol Psychiatry*. 2013; 40:267–272. [PubMed: 23085508]
134. Pincus D, Kose S, Arana A, et al. Inverse effects of oxytocin on attributing mental activity to others in depressed and healthy subjects: a double-blind placebo controlled fMRI study. *Front Psychiatry*. 2010; 1:134. [PubMed: 21423444]
135. O'Connor L, Berry J, Weiss J, et al. Guilt, fear, submission, and empathy in depression. *J Affect Disord*. 2002; 71:13–19.
136. Scantamburlo G, Hansenne M, Geenen V, et al. Additional intranasal oxytocin to escitalopram improves depressive symptoms in resistant depression: an open trial. *Eur Psychiatry*. 2015; 30:65–68. [PubMed: 25282363]
137. Domes G, Normann C, Heinrichs M. The effect of oxytocin on attention to angry and happy faces in chronic depression. *BMC Psychiatry*. 2016; 16:92. [PubMed: 27048333]
138. Cardoso C, Ellenbogen MA. Oxytocin and psychotherapy: keeping context and person in mind. *Psychoneuroendocrinology*. 2013; 38:3172–3173. [PubMed: 24035601]
139. Yatzkar U, Klein E. Intranasal oxytocin in patients with posttraumatic stress disorder: a single dose, pilot double blind crossover study. *Eur Neuropsychopharm*. 2010; 20:S84.
140. Pitman RK, Orr SP, Lasko NB. Effects of intranasal vasopressin and oxytocin on physiologic responding during personal combat imagery in Vietnam veterans with posttraumatic stress disorder. *Psychiatry Res*. 1993; 48:107–117. [PubMed: 8416021]
141. Koch SB, van Zuiden M, Nawijn L, et al. Intranasal oxytocin administration dampens amygdala reactivity towards emotional faces in male and female PTSD patients. *Neuropsychopharmacology*. 2016; 41:1495–1504. [PubMed: 26404844]
142. Koch SB, van Zuiden M, Nawijn L, et al. Intranasal oxytocin normalizes amygdala functional connectivity in post-traumatic stress disorder. *Neuropsychopharmacology*. 2016; 41:2041–2051. [PubMed: 26741286]
143. Nawijn L, van Zuiden M, Koch SB, et al. Intranasal oxytocin enhances neural processing of monetary reward and loss in post-traumatic stress disorder and traumatized controls. *Psychoneuroendocrinology*. 2016; 66:228–237. [PubMed: 26851698]
144. Beevers CG, Lee H, Wells TT. Association of predeployment gaze bias for emotion stimuli with later symptoms of PTSD and depression in soldiers deployed in Iraq. *Am J Psychiat*. 2011; 168:735–741. [PubMed: 21454916]
145. Grillon C, Krinsky M, Charney DR, et al. Oxytocin increases anxiety to unpredictable threat. *Mol Psychiatr*. 2013; 18:958–960.
146. Schneiderman I, Zagoory-Sharon O, Leckman JF, et al. Oxytocin during the initial stages of romantic attachment: relations to couples' interactive reciprocity. *Psychoneuroendocrinology*. 2012; 37:1277–1285. [PubMed: 22281209]
147. Weisman O, Zagoory-Sharon O, Schneiderman I, et al. Plasma oxytocin distributions in a large cohort of women and men and their gender-specific associations with anxiety. *Psychoneuroendocrinology*. 2013; 38:694–701. [PubMed: 22999263]
148. Holt-Lunstad J, Birmingham W, Light KC. The influence of depressive symptomatology and perceived stress on plasma and salivary oxytocin before, during and after a support enhancement intervention. *Psychoneuroendocrinology*. 2011; 36:1249–1256. [PubMed: 21507578]
149. Bos PA, Panksepp J, Bluthé RM, et al. Acute effects of steroid hormones and neuropeptides on human social-emotional behavior: a review of single administration studies. *Front Neuroendocrin*. 2012; 33:17–35.
150. Windle RJ, Gamble LE, Kershaw YM, et al. Gonadal steroid modulation of stress-induced hypothalamo-pituitary-adrenal activity and anxiety behavior: role of central oxytocin. *Endocrinology*. 2006; 147:2423–2431. [PubMed: 16439458]
151. Richard S, Zingg HH. The human oxytocin gene promoter is regulated by estrogens. *J Biol Chem*. 1990; 265:6098–6103. [PubMed: 2108152]

152. Ebner NC, Chen H, Porges E, et al. Oxytocin's effect on resting-state functional connectivity varies by age and sex. *Psychoneuroendocrinology*. 2016; 69:50–59. [PubMed: 27032063]
153. Kubansky L, Mendes W, Appleton A, et al. A heartfelt response: oxytocin effects on response to social stress in men and women. *Biol Psychol*. 2012; 90:1–9. [PubMed: 22387929]
154. Hurlemann R, Patin A, Onur OA, et al. Oxytocin enhances amygdala-dependent, socially reinforced learning and emotional empathy in humans. *J Neurosci*. 2010; 30:4999–5007. [PubMed: 20371820]
155. Rilling JK, DeMarco AC, Hackett PD, et al. Sex differences in the neural and behavioral response to intranasal oxytocin and vasopressin during human social interaction. *Psychoneuroendocrinology*. 2014; 39:237–248.
156. Gao S, Becker B, Luo L, et al. Oxytocin, the peptide that bonds the sexes also divides them. *Proc Natl Acad Sci USA*. 2016; 113:7650–7654. [PubMed: 27325780]
157. Feifel D, MacDonald K, McKinney R, et al. A randomized, placebo-controlled investigation of intranasal oxytocin in patients with anxiety. *Neuropsychopharmacology*. 2011; 36:S324–S449.
158. Domes G, Lischke A, Berger C, et al. Effects of intranasal oxytocin on emotional face processing in women. *Psychoneuroendocrinology*. 2010; 35:83–93. [PubMed: 19632787]
159. Lischke A, Gamer M, Berger C, et al. Oxytocin increases amygdala reactivity to threatening scenes in females. *Psychoneuroendocrinology*. 2012; 37:1431–1438. [PubMed: 22365820]
160. Cardoso C, Ellenbogen MA, Linnen AM. Acute intra-nasal oxytocin improves positive self-perceptions of personality. *Psychopharmacol (Berl)*. 2012; 220:741–749.
161. Theodoridou A, Rowe AC, Penton-Voak IS, et al. Oxytocin and social perception: oxytocin increases perceived facial trustworthiness and attractiveness. *Horm Behav*. 2009; 56:128–132. [PubMed: 19344725]
162. Gangestad SW. An evolutionary perspective on oxytocin and its behavioral effects. *Curr Opin Psychol*. 2016; 7:115–119.
163. Heim C, Newport DJ, Mletzko T, et al. The link between childhood trauma and depression: insights from HPA axis studies in humans. *Psychoneuroendocrinology*. 2008; 33:693–710. [PubMed: 18602762]
164. Breslau N, Koenen KC, Luo Z, et al. Childhood maltreatment, juvenile disorders and adult post-traumatic stress disorder: a prospective investigation. *Psychol Med*. 2014; 44:1937–1945. [PubMed: 24168779]
165. Mikulincer M, Shaver PR. An attachment perspective on psychopathology. *World Psychiatry*. 2012; 11:11–15. [PubMed: 22294997]
166. Heim C, Young LJ, Newport DJ, et al. Lower CSF oxytocin concentrations in women with a history of childhood abuse. *Mol Psychiatry*. 2009; 14:954–958.
167. Grimm S, Pestke K, Feeser M, et al. Early life stress modulates oxytocin effects on limbic system during acute psychosocial stress. *Soc Cogn Affect Neurosci*. 2014; 9:1828–1835. [PubMed: 24478326]
168. Meinlschmidt G, Heim C. Sensitivity to intranasal oxytocin in adult men with early parental separation. *Biol Psychiatry*. 2007; 61:1109–1111. [PubMed: 17141739]
169. Bakermans-Kranenburg MJ, van Ijzendoorn MH, Riem MM, et al. Oxytocin decreases handgrip force in reaction to infant crying in females without harsh parenting experiences. *Soc Cogn Affect Neurosci*. 2012; 7:951–957. [PubMed: 22037689]
170. Bartz JA, Zaki J, Ochsner KN, et al. Effects of oxytocin on recollections of maternal care and closeness. *Proc Natl Acad Sci USA*. 2010; 107:21371–21375. [PubMed: 21115834]
171. Riem MM, Bakermans-Kranenburg MJ, Voorthuis A, et al. Oxytocin effects on mind-reading are moderated by experiences of maternal love withdrawal: an fMRI study. *Prog Neuropsychopharmacol Biol Psychiatry*. 2014; 51:105–112. [PubMed: 24486563]
172. Fan Y, Pestke K, Feeser M, et al. Amygdala-hippocampal connectivity changes during acute psychosocial stress: joint effect of early life stress and oxytocin. *Neuropsychopharmacology*. 2015; 40:2736–2744. [PubMed: 25924202]
173. Buchheim A, Heinrichs M, George C, et al. Oxytocin enhances the experience of attachment security. *Psychoneuroendocrinology*. 2009; 34:1417–1422. [PubMed: 19457618]

174. Bartz JA, Lydon JE, Kolevzon A, et al. Differential effects of oxytocin on agency and communion for anxiously and avoidantly attached individuals. *Psychol Sci.* 2015; 26:1177–1186. [PubMed: 26122122]
175. De Dreu CK. Oxytocin modulates the link between adult attachment and cooperation through reduced betrayal aversion. *Psychoneuroendocrinology.* 2012; 37:871–880. [PubMed: 22055739]
176. Riem MM, van Ijzendoorn MH, Tops M, et al. Oxytocin effects on complex brain networks are moderated by experiences of maternal love withdrawal. *Neuropsychopharmacology.* 2013; 23:1288–1295.
177. Kumsta R, Heinrichs M. Oxytocin, stress and social behavior: neurogenetics of the human oxytocin system. *Curr Opin Neurobiol.* 2013; 23:11–16. [PubMed: 23040540]
178. Feldman R, Monakhov M, Pratt M, et al. Oxytocin pathway genes: evolutionary ancient system impacting on human affiliation, sociality, and psychopathology. *Biol Psychiat.* 2016; 79:174–184. [PubMed: 26392129]
179. Bradley B, Westen D, Mercer KB, et al. Association between childhood maltreatment and adult emotional dysregulation in a low-income, urban, African American sample: moderation by oxytocin receptor gene. *Dev Psychopathol.* 2011; 23:439–452. [PubMed: 23786688]
180. Brüne M. Does the oxytocin receptor (OXTR) polymorphism (rs2254298) confer ‘vulnerability’ for psycho-pathology or ‘differential susceptibility’? Insights from evolution (opinion). *BMC Med.* 2012; 10:38. [PubMed: 22510359]
181. Kim HS, Sherman DK, Sasaki JY, et al. Culture, distress, and oxytocin receptor polymorphism (OXTR) interact to influence emotional support seeking. *Proc Natl Acad Sci USA.* 2010; 107:15717–15721. [PubMed: 20724662]
182. Krueger F, Parasuraman R, Iyengar V, et al. Oxytocin receptor genetic variation promotes human trust behavior. *Front Hum Neurosci.* 2012; 6:4. [PubMed: 22347177]
183. Chen FS, Kumsta R, von Dawans B, et al. Common oxytocin receptor gene (OXTR) polymorphism and social support interact to reduce stress in humans. *Proc Natl Acad Sci USA.* 2011; 108:19937–19942. [PubMed: 22123970]
184. Tost H, Kolachana B, Hakimi S, et al. A common allele in the oxytocin receptor gene (OXTR) impacts prosocial temperament and human hypothalamic-limbic structure and function. *Proc Natl Acad Sci USA.* 2010; 107:13936–13941. [PubMed: 20647384]
185. McQuaid RJ, McInnis OA, Matheson K, et al. Oxytocin and social sensitivity: gene polymorphisms in relation to depressive symptoms and suicidal ideation. *Front Hum Neurosci.* 2016; 10:358. [PubMed: 27486392]
186. Quirin M, Kuhl J, Dusing R. Oxytocin buffers cortisol responses to stress in individuals with impaired emotion regulation abilities. *Psychoneuroendocrinology.* 2011; 36:898–904. [PubMed: 21208748]
187. Human LJ, Thorson KR, Mendes WB. Interactive effects between extraversion and oxytocin administration: implications for positive social processes. *Soc Psychol Person Sci.* 2016; 7:735–744.
188. Bartz JA, Zaki J, Bolger N, et al. Oxytocin selectively improves empathic accuracy. *Psychol Sci.* 2010; 21:1426–1428. [PubMed: 20855907]
189. Xu L, Ma X, Zhao W, et al. Oxytocin enhances attentional bias for neutral and positive expression faces in individuals with higher autistic traits. *Psychoneuroendocrinology.* 2015; 62:352–358. [PubMed: 26372768]
190. Scheele D, Kendrick KM, Khouri C, et al. An oxytocin-induced facilitation of neural and emotional responses to social touch correlates inversely with autism traits. *Neuropsychopharmacology.* 2014; 39:2078–2085. [PubMed: 24694924]
191. Furst A, Thron J, Scheele D, et al. The neuropeptide oxytocin modulates consumer brand relationships. *Sci Rep.* 2015; 5:14960. [PubMed: 26449882]
192. De Dreu CK, Greer LL, Handgraaf MJ, et al. The neuropeptide oxytocin regulates parochial altruism in intergroup conflict among humans. *Science.* 2010; 328:1408–1411. [PubMed: 20538951]
193. Zheng H, Kendrick KM, Yu R. Fear or greed? Oxytocin regulates inter-individual conflict by enhancing fear in men. *Horm Behav.* 2016; 85:12–18. [PubMed: 27444251]

194. Heinrichs M, Baumgartner T, Kirschbaum C, et al. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. *Biol Psychiat*. 2003; 54:1389–1398. [PubMed: 14675803]
195. Cardoso C, Valkanas H, Serravalle L, et al. Oxytocin and social context moderate social support seeking in women during negative memory recall. *Psychoneuroendocrinology*. 2016; 70:63–69. [PubMed: 27164224]
196. Insel TR. Translating oxytocin neuroscience to the clinic: a National Institute of Mental Health perspective. *Biol Psychiat*. 2016; 79:153–154. [PubMed: 26723108]
197. Lane A, Luminet O, Nave G, et al. Is there a publication bias in behavioural intranasal oxytocin research on humans? Opening the file drawer of one laboratory. *J Neuroendocrinol*. 2016; : 28.doi: 10.1111/jne.12384
198. Lane A, Mikolajczak M, Treinen E, et al. Failed replication of oxytocin effects on trust: the envelope task case. *PloS One*. 2015; 10:e0137000. [PubMed: 26368396]
199. Hofmann SG, Fang A, Brager DN. Effect of intranasal oxytocin administration on psychiatric symptoms: a meta-analysis of placebo-controlled studies. *Psychiat Res*. 2015; 228:708–714.
200. Hofmann SG, Fang A, Brager DN. Notice of retraction and replacement: Hofmann et al.Effect of intranasal oxytocin administration on psychiatric symptoms: A meta-analysis of placebo-controlled studies. *Psychiatry Res*. 2015; 228:708–714. [accessed 22 December 2016] http://retractionwatch.com/wp-content/uploads/2016/10/Retraction-Letter_Hofmann-et-al.pdf. [PubMed: 26094200]
201. Walum H, Waldman ID, Young LJ. Statistical and methodological considerations for the interpretation of intranasal oxytocin studies. *Biol Psychiatry*. 2015; 79:251–257. [PubMed: 26210057]
202. Scheele D, Plota J, Stoffel-Wagner B, et al. Hormonal contraceptives suppress oxytocin-induced brain reward responses to the partner’s face. *Soc Cogn Affect Neur*. 2016; 11:767–774.
203. Nillni YI, Pineles SL, Patton SC, et al. Menstrual cycle effects on psychological symptoms in women with PTSD. *J Trauma Stress*. 2015; 28:1–7. [PubMed: 25613589]




Figure 1. Mechanisms of stress-related disorders that may be modified by intranasal oxytocin and moderated by individual differences and contextual cues. Source: Adapted with permission from Olf et al.³⁸